What is the Origin of CJC-1295 Peptide?

This peptide's nomenclature reflects its developmental history as a research compound designed to improve upon the pharmacokinetic limitations of naturally occurring GHRH. The structure incorporates an amino acid modification that binds to albumin, effectively extending its duration of action in the human physiology domain. Its genesis is rooted in enhancing therapeutic potential for GH deficiency states.

What is the Mechanism of CJC-1295 Peptide?

CJC-1295 functions by binding to the GHRH receptor on pituitary somatotrophs, mimicking the action of endogenous GHRH to initiate the signaling cascade involving adenylyl cyclase and subsequent cAMP production. This intracellular signaling culminates in the transcription and secretion of Growth Hormone. The albumin-binding moiety prevents rapid renal clearance, allowing for sustained receptor stimulation over days rather than minutes. This sustained signaling is key to its physiological effect profile.

CJC-1295 Peptide ∞ Area

CJC-1295 Peptide

Meaning

CJC-1295 Peptide is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH) specifically modified to exhibit a prolonged half-life within the systemic circulation. Clinically, it is utilized to stimulate the somatotropic axis, promoting pulsatile release of endogenous Growth Hormone (GH) from the anterior pituitary gland. This compound offers a sustained stimulus compared to native GHRH, which is rapidly degraded. Accurate application requires understanding its interaction with pituitary somatotrophs.